Why this matters

This isn’t ordinary tiredness. It’s the kind of exhaustion that sleep doesn’t fix, and there are real reasons why.

When the immune system is active, it sends signals that slow the body down and pull energy away from daily life, think of it like a background programme running constantly, using up battery even when it isn’t visible. Treatments can add to this drain, as many medicines used to manage immune conditions come with tiredness as a side effect. Low iron or vitamin deficiencies make it harder still, reducing the body's ability to carry oxygen and keep up with daily demands. When pain or stress disrupts sleep on top of all that, the body rarely gets the chance to fully recharge.

Even when test results look fine, these processes can keep running quietly in the background for weeks. That’s why fatigue often sticks around longer than expected.

What could help

A few things that can make a difference:

• Break tasks into smaller steps with rest in between, rather than pushing through and crashing later
• Talk to your doctor if fatigue is severe: things like low iron, certain vitamin levels, or thyroid issues are treatable and worth checking
• Gentle movement, done regularly, can actually help your energy levels over time without overdoing it
• Tracking when fatigue is better or worse can reveal patterns that are easy to miss

Above all, be kind to yourself. Fatigue is a symptom, not a failing.

Understanding why it happens can make it easier to explain to the people around you, and to ease some of the guilt that comes with needing more rest than you used to.

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

References:

'Benefits of exercise in rheumatoid arthritis' (2011) https://doi.org/10.4061/2011/681640

'Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases' (2010) https://doi.org/10.1111/j.1365-2796.2010.02218.x

'Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored' (2005) https://doi.org/10.1002/art.21450

What clinicians mean by “stable”

When a clinician says your condition is stable, it means disease activity is low, there isn’t evidence of further organ damage, and tests show no progression, clear signs that the treatment is working as intended. Stability isn’t permanent, though; it requires ongoing management, so medication is usually continued, and regular monitoring remains important. Some symptoms may still be present because stability reflects control and the absence of deterioration rather than a cure. Regular reviews help to identify any early changes and ensure any issues are addressed promptly, before they become more serious.

What Specialists Are Checking

• Disease activity is low or absent
• No new organ involvement
• Treatment is working without unacceptable side effects
• No progression of damage

What Could Help

Stability gives you more life back, but it still needs ongoing attention.

• Keep taking medicines as prescribed; discuss any changes before stopping.
• Attend reviews and tests on schedule; monitoring catches early changes and can detect problems before they become serious. Ask how often monitoring is needed.
• Track symptoms and function briefly
• Ask which signs should trigger earlier contact or a treatment change.
• Support stability with pacing, good sleep, stress management, and avoiding known triggers.
• Request a review if flares increase or new symptoms appear.

If you're stable, that's genuinely worth celebrating.

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

References:

‘Rheumatoid arthritis in adults: management’ (2022) https://www.nice.org.uk/guidance/ng100

‘Treating rheumatoid arthritis to target: recommendations of an international task force' (2010) https://doi.org/10.1136/ard.2009.123919

Why this matters

Hearing "nothing serious is wrong" when still feeling unwell can be deeply frustrating. It can feel like being dismissed rather than reassured. But the two aren’t the same and knowing the difference matters both for accepting appropriate outcomes and for recognising when to push back.

What medical reassurance actually means

Reassurance in medicine means that a serious, progressive, or life-threatening disease has been reasonably excluded based on clinical assessment and appropriate investigations. It doesn’t mean symptoms are imaginary, that nothing could ever be wrong, or that further investigation might not be needed if things change. Reassurance is probabilistic, not absolute. It means that based on current evidence, a serious disease is very unlikely.

When reassurance is appropriate

Reassurance is a valid clinical outcome in several situations:

• Symptoms are common and usually benign. Fatigue, headaches, joint pain, and abdominal discomfort usually have benign causes, and testing everyone extensively generates more false positives than true diagnoses
• Tests have adequately excluded serious pathology. If appropriate investigations are normal, reassurance is justified
• Natural history supports observation. Some conditions resolve spontaneously within predictable timeframes
• Further investigation would cause more harm than benefit. When false positive rates are high, incidental findings are likely, or procedures are invasive, the harms can outweigh the benefits
• Symptoms are consistent with a functional disorder. Functional disorders cause real symptoms without structural pathology detectable on tests. Reassurance that a serious disease is excluded is appropriate while still validating that symptoms are real

What good reassurance looks like versus dismissal

Appropriate reassurance includes acknowledgment of symptoms, a clear explanation of what was tested and what those results mean, a discussion of possible causes, a plan for managing symptoms, safety netting around what to watch for, and a follow-up arrangement.

Dismissal looks different. It’s "your tests are fine, nothing is wrong" with no explanation, no plan, and no acknowledgement. If reassurance feels dismissive, it’s worth asking: "Can you help me understand what’s been ruled out and what might be causing these symptoms?" and "What would mean I should come back sooner?"

When to push back

Pushing back is appropriate when symptoms are worsening progressively, when new symptoms suggest evolving disease, when basic investigations haven’t been done, when functional impact is severe, or when red flags such as unexplained weight loss or night sweats haven’t been properly investigated.

What you could do

Accepting reassurance is easier when the process behind it’s clear, and the clinician has genuinely engaged with the symptoms.

• If a "nothing serious" outcome feels incomplete, ask what specifically was checked and what the next step would be if symptoms persist or change
• If health anxiety makes it difficult to accept reassurance even after appropriate investigation, that’s worth raising directly as something to address in its own right
• Track symptoms over time so that if things do change, there’s a clear record to bring to the next appointment

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

References:

‘Management of functional somatic syndromes and bodily distress’ (2018) https://doi.org/10.1159/000484413

‘Patients' perceptions of medical explanations for somatisation disorders: qualitative analysis’ (1999) https://doi.org/10.1136/bmj.318.7180.372

Why this matters

Appointments tend to focus on current symptoms and immediate treatment decisions. What isn’t always discussed is what the clinician is weighing in the background: the risks being managed, the trade-offs being made, and the uncertainties they are navigating. Knowing what those concerns tend to be helps make sense of decisions that might otherwise feel cautious, slow, or unclear.

What clinicians worry about

When prescribing long-term immunosuppression. Infection risk is a significant concern. Immunosuppression increases vulnerability to serious infections, including pneumonia, sepsis, and reactivation of latent infections. There’s also a small but recognised increase in lymphoma and skin cancer risk with long-term use of some medications. Clinicians also think carefully about medication non-adherence, as stopping treatment without discussion can cause preventable flares, and about fertility and pregnancy, since many immunosuppressants are unsafe during pregnancy and unplanned pregnancies create serious risks.

When disease appears mild but could progress. In conditions like rheumatoid arthritis, there’s a window of opportunity where early treatment prevents irreversible damage. Clinicians sometimes push for treatment even when symptoms feel manageable, precisely because waiting risks harm that cannot be undone. They also hold uncertainty about which patients will stay stable and which will progress rapidly, and that uncertainty informs recommendations even when it’s not spelt out.

When symptoms are vague or unexplained. The differential diagnosis for vague symptoms is wide, and clinicians worry about missing something serious while also being aware that testing everything generates false positives. They may also be considering whether psychological factors are contributing but hesitate to raise this for fear of seeming dismissive.

When long-term outcomes are uncertain. Clinicians often cannot predict how a condition will evolve over the next ten to twenty years. Current treatment might work well for a long time or may need changing sooner than expected. These uncertainties shape decisions but rarely make it into the conversation.

What you could do

Asking directly tends to open the conversation more than waiting for information to be offered.

• Ask: "What are your main concerns about my condition or treatment right now?"
• Ask: "What complications are we trying to prevent, and what are the trade-offs?"
• Share complete information including all medications, supplements, any adherence difficulties, and relevant mental health or social circumstances
• Accept that clinicians are working with probabilities, not certainties, and that uncertainty isn’t the same as not knowing what to do

Understanding what sits behind clinical decisions transforms appointments from passive information-receiving into a genuine partnership.

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

References:

‘A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis’ (2008) https://pubmed.ncbi.nlm.nih.gov/18433475/

‘Applying early intervention strategies to autoimmune skin diseases: is the window of opportunity preclinical? A Dermato-Rheumatology Perspective’ (2022)x https://www.sciencedirect.com/science/article/pii/S0022202X2102532X

‘Lymphoma risk in autoimmune diseases with multiple medication use: analysis from the LIFE Study’ (2025) https://doi.org/10.1038/s41408-025-01422-6

‘The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation’ (2016) https://doi.org/10.1136/annrheumdis-2015-208840

‘What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review’ (2014) https://doi.org/10.1136/annrheumdis-2012-203130

Why this matters

What begins as useful monitoring can gradually become something more consuming. The line between staying informed and becoming preoccupied with every fluctuation is easy to cross, particularly when living with uncertainty feels threatening. Tracking that creates more anxiety than it relieves is no longer serving its purpose.

When tracking becomes problematic

The difference between healthy and unhealthy tracking often comes down to frequency and intention. Healthy tracking captures what’s clinically useful at defined intervals. Problematic tracking involves checking symptoms multiple times a day, scanning the body for any sensation, recording every minor fluctuation, and feeling temporarily relieved by stable results only for anxiety to return quickly.

A useful signal: if tracking is creating more worry than it’s resolving, something has shifted.

How to track purposefully

Track at defined times rather than continuously. Choose specific moments, once daily or a few times a week, and resist the urge to check in between. When the urge arises, notice it, acknowledge it, and refocus elsewhere.

Before logging something, ask whether it would actually change anything clinically or help a clinician. If the answer is no, it may not need recording. Using structured tools with set prompts helps with this, as they limit over-elaboration and keep tracking focused on what matters.

Set a time boundary. Tracking should take no more than 5 to 10 minutes. If it regularly takes longer, something is being over-recorded. Log symptoms and move on rather than analysing them immediately. Reviewing trends weekly or monthly provides useful pattern recognition without constant preoccupation.

It also helps to recognise that all symptoms fluctuate. Pain varying between 4 and 6 is normal variation, not a meaningful change. There’s an important difference between noticing symptoms and obsessively scanning for them.

Finally, if tracking is consistently creating anxiety rather than relieving it, taking a planned break for a week, where clinically safe, can provide a useful perspective. Many people find that life feels better without constant tracking, and that periodic tracking provides sufficient information.

When to track more and when to track less

Tracking more intensively makes sense when starting a new medication that requires monitoring, during a flare, when preparing for a medical appointment, or when the disease is unstable, and patterns are still emerging.

Tracking less intensively is worth considering when the disease is stable, when tracking is creating significant anxiety, when in diagnostic limbo where results won’t change management, or when constant tracking has started to reinforce an illness identity rather than support day-to-day life.

What you could do

Tracking works best when it feels like a tool rather than a compulsion. If it’s started to feel like the latter, that’s worth acknowledging.

• If the urge to check between scheduled times comes up, notice it and redirect attention rather than acting on it
• If tracking is consistently causing more anxiety than it relieves, consider discussing this with a clinician
• Structured tools with set prompts help keep tracking focused and time-limited

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

References:

‘Fear of the unknown: one fear to rule them all?’ (2016) https://doi.org/10.1016/j.janxdis.2016.03.011

‘Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations’ (2008) https://doi.org/10.1016/j.jpain.2007.09.005

[Secondary Action]: Explore your health trends over time with mOI - Button CT

Why this matters

When more testing seems reassuring, excessive testing can actually create anxiety, trigger unnecessary treatments, and paradoxically harm health. What matters is whether a test is asking the right question at the right time, and whether the result will actually change what happens next.

The problems with over testing

False positives and incidental findings. Every test carries a small chance of returning an abnormal result that isn’t clinically significant. The more tests carried out, the higher the probability of finding something that looks concerning but is actually normal variation. Testing 20 different markers gives a healthy person roughly a 64% chance of at least one abnormal result by pure chance. These findings then trigger further testing and sometimes invasive procedures for something that would never have caused harm.

Overdiagnosis and unnecessary treatment. Finding a disease that would never cause symptoms leads to treatment carrying risks without benefit.

Anxiety and financial cost. Frequent testing increases anxiety rather than reducing it. Reassuring results provide temporary relief, but anxiety returns and prompts more testing, creating a cycle that’s difficult to break. Private testing is also expensive, and that money could go towards things that provide genuine benefits.

When testing genuinely helps

Testing is valuable when there’s a clear clinical question, when the result will change what happens next, and when the benefits outweigh the risks of finding something incidental. Evidence-based monitoring protocols exist precisely for this reason.

What you could do

Understanding the purpose behind each test makes it easier to trust the process rather than add to it out of anxiety.

• Before requesting or agreeing to additional testing, ask whether the result would change anything. If the answer is no or unclear, the test may not be necessary
• Trust evidence-based monitoring schedules rather than seeking tests more frequently than recommended. Guidelines define appropriate intervals for good reasons
• If anxiety is driving the desire to test more, addressing the anxiety directly is more effective and avoids the reinforcement cycle
• If symptoms persist despite reassuring tests, or if a diagnosis remains unclear and affects management, further testing is genuinely justified. This is different from reassurance-seeking

Purposeful, well-timed testing supports good care. Testing driven by anxiety or the hope that more information will always help doesn’t.

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

References:

‘Preventing overdiagnosis: how to stop harming the healthy’ (2012) https://doi.org/10.1136/bmj.e3502

‘Psychological Treatment of Health Anxiety and Hypochondriasis: A Biopsychosocial Approach’ (2008) https://psycnet.apa.org/record/2008-10831-000

‘The cascade effect in the clinical care of patients’ (1986) https://doi.org/10.1056/NEJM198602203140809

Why this matters

When feeling reasonably well, the volume of monitoring appointments and blood tests can start to feel disproportionate. However disease activity and medication side effects can develop without any noticeable symptoms, which is precisely why monitoring is preventive rather than reactive. Understanding what each test is designed to catch, and why, makes it easier to stay engaged even when symptoms are quiet.

The three purposes of long-term monitoring

Detecting disease activity that has no symptoms yet. Some immune conditions can be active without producing obvious signs. Kidney involvement in lupus, for example, can progress silently for months, with no pain or swelling. Routine monitoring catches changes before permanent damage occurs.

Keeping an eye on medication safety. Many immunosuppressant medications are effective precisely because they are powerful, and that same potency requires ongoing surveillance. Liver toxicity, bone marrow suppression, and kidney damage can all develop gradually without warning signs. Regular blood tests allow the clinical team to catch these early and adjust treatment before harm occurs.

Screening for long-term complications. Chronic inflammation and long-term medication use increase the risk of secondary conditions: cardiovascular disease, osteoporosis, infections, and, in some cases, malignancy. Screening means that if these begin to develop, they are identified early enough to be managed well.

What specific tests are looking for

Some common examples of what long-term monitoring looks at:

• Full blood count (FBC): Checks for anaemia, low white cell count from medication, and low platelets. Catching these early allows for dose adjustment before serious complications develop.
• Liver function tests (LFTs): Monitors for liver stress caused by methotrexate, other DMARDs, and some biologics. Early detection makes it possible to stop or reduce the medication before further damage occurs.
• Kidney function and urine tests: Assesses for kidney involvement from the disease itself or from medication toxicity. Kidney damage is often irreversible if undetected, so catching changes early is particularly important.
• Urinalysis: Looks for protein or blood in the urine, both of which can signal kidney inflammation. These changes often appear before any symptoms, making this a key early-warning tool.
• Inflammatory markers (CRP, ESR): Measures levels of inflammation in the body. Rising markers, even without obvious symptoms, can indicate subclinical disease activity and help the team anticipate flares before they escalate.
• Lipid Profile: Chronic inflammation and long-term steroid use can raise cholesterol. Cardiovascular disease is one of the leading causes of long-term complications in autoimmune conditions, so managing cholesterol and blood pressure early reduces that risk meaningfully.
• Bone density scans (DEXA): Assesses bone density, particularly for people who have taken steroids long-term. Osteoporosis develops gradually, so early detection allows for preventive treatment that significantly reduces fracture risk.
• Eye Examinations: Hydroxychloroquine, commonly used in lupus and rheumatoid arthritis, can rarely affect the retina over time. Steroid use can also increase the risk of cataracts and glaucoma, both of which are manageable when identified early.

What you could do

Understanding the purpose behind each test makes the process feel less like an inconvenience and more like something working in your favour.

• Ask about each test at your next appointment: "What’s this checking for, and how often do I need it?"
• Keep your own record of results over time. Trends across appointments are more informative than any single result in isolation.
• If attending appointments is difficult due to mobility, transport, or anxiety around needles, raise it with your clinical team. Accommodations can often be arranged.
• Set reminders for monitoring that’s less frequent, such as annual eye exams or two-yearly bone density scans, so nothing gets missed during a period of stability.

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

References:

‘EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders’ (2017) https://ard.eular.org/article/S0003-4967(24)01571-1/fulltext

‘Joint EULAR and ERA-EDTA recommendations for the management of adult and paediatric lupus nephritis’ (2012) https://ard.eular.org/article/S0003-4967(24)18625-6/fulltext

‘Rheumatoid arthritis in adults: management (NICE guideline NG100)’ (2022) https://www.nice.org.uk/guidance/ng100

Why this matters

When treatment isn’t working as hoped, waiting weeks or months for an adjustment can feel frustrating. Understanding the clinical reasoning behind the pace makes it easier to trust the process and to recognise the situations where faster action is genuinely warranted.

Why changes are slow

• One variable at a time. Changing multiple things simultaneously makes it impossible to know what worked or caused problems. Sequential adjustments produce clearer cause-and-effect information, which informs every subsequent treatment decision
• Assessing true response takes time. Medications take weeks to months to reach full effect, and changing treatment before that window closes risks abandoning something that would have worked
• Starting low and increasing gradually. High starting doses often cause side effects that lead to treatment being stopped entirely. Gradual escalation allows tolerance to develop and improves the chance of reaching a therapeutic dose
• Safety monitoring between changes. Some medications require blood counts, liver, or kidney function to be checked before doses are increased. Skipping this risks toxicity going undetected
• Drug interactions and complexity. When multiple medications are involved, sequential adjustments are safer than changing several things at once

When slow changes are appropriate

• Stable disease with minor symptoms. Cautious dose optimisation avoids destabilising what’s already largely controlled
• Starting a new treatment. Established dose escalation protocols are slower but evidence-based
• Complex comorbidities. Multiple conditions, organ impairment, or extensive medication lists all require extra caution
• Older patients. Drug metabolism differs with age, and side effect risk is higher

When speed is justified

Slow isn’t always appropriate. Rapid escalation is warranted when the disease is severe and causing organ damage or significant functional impairment. It’s also justified when treatment has clearly failed after an adequate trial, when side effects are intolerable, or when there’s a high risk of irreversible damage where urgency outweighs the case for caution.

What you could do

• If the pace of change feels too slow, ask directly: "My symptoms are significantly affecting my quality of life. Can we discuss whether faster escalation is safe?" or "What evidence would convince you that current treatment has failed?"
• Communicate functional impact clearly. If symptoms are making daily life very difficult, escalation may be justified and that case is worth making
• Balance patience with advocacy. Adequate trials are needed, but prolonged delay while suffering is unacceptable
• Track medication timing, doses, and symptom changes so that the clinical team has clear evidence to work with at the next review

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

References:

‘Comparing myelosuppression frequency in Indian inflammatory bowel disease patients: a randomized trial of full dose versus gradual escalation of thiopurines’ (2024) https://www.cureus.com/articles/210109-comparing-myelosuppression-frequency-in-indian-inflammatory-bowel-disease-patients-a-randomized-trial-of-full-dose-versus-gradual-escalation-of-thiopurines#!/

‘EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update’ (2020) https://doi.org/10.1136/annrheumdis-2019-216655

‘Rheumatoid arthritis in adults: management (NICE guideline NG100)’ (2022) https://www.nice.org.uk/guidance/ng100

Why this matters

Attributing symptoms incorrectly leads to poor treatment decisions. Blaming effective medication for symptoms that are actually caused by disease activity risks stopping a treatment unnecessarily. Assuming worsening is disease progression when it’s actually a side effect risks persisting with something that’s causing harm. In both cases, the clinical team needs accurate information to make the right call.

How to distinguish them

Timing is the most useful starting point. Side effects typically emerge within days to weeks of starting a new medication, after dose increases, or when new interacting medications are added. Disease symptoms tend to predate medication, worsen when treatment is reduced or stopped, or follow known flare triggers such as infection or stress. A useful question to ask is: did this symptom appear only after starting or changing medication?

The known side effect profile of the medication also helps. Every medication has predictable side effects. If a symptom isn’t on that list, it’s less likely to be medication-related. For example, methotrexate commonly causes nausea and hair thinning but rarely causes joint pain. Therefore, joint pain in someone taking methotrexate for arthritis is more likely a sign of disease activity than a side effect.

Symptom characteristics provide further clues. New symptom types that have never been experienced before may be side effects. Symptoms that worsen after doses suggest a drug-related cause. Symptoms that improve on drug holidays suggest side effects. Familiar symptom patterns that match previous disease activity are more likely to represent the condition itself.

Objective markers can help resolve ambiguity. Rising inflammatory markers suggest disease activity, not side effects. Abnormal liver function tests suggest medication toxicity, if on a hepatotoxic drug. Normal inflammatory markers alongside worsening symptoms make a medication cause more likely.

Common scenarios that can be confusing

• Fatigue. Both disease and many medications cause it. Tracking whether fatigue correlates with dose timing or with disease activity markers helps distinguish the two
• Nausea. If it peaks a few hours after taking medication and improves with dose changes or anti-nausea measures, it’s likely medication-related
• Rashes. Both immune conditions and medications cause rashes. Timing relative to starting treatment, distribution, and associated features all help differentiate

What you could do

• Don’t stop medication abruptly if side effects are suspected. Contact the GP or specialist first, as many are manageable without stopping treatment
• Document clearly when symptoms started, how they relate to medication doses, their severity, and any patterns
• Report symptoms without concluding the cause. A clinician can assess probability based on pharmacology, disease patterns, and examination far more reliably than self-attribution alone
• Track symptoms and medication together so that timing relationships become visible over time

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

References:

‘Diagnosis and management of rheumatoid arthritis: a review’ (2018) https://doi.org/10.1001/jama.2018.13103

‘Joining the DoTS: new approach to classifying adverse drug reactions’ (2003) https://doi.org/10.1136/bmj.327.7425.1222